Skip to main content

Table 3 Patients with ≥ 10 or < 10 acute migraine-specific medication days

From: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Acute Migraine-Specific Medication Days

Baseline

N = 145 (100%)

Month 6

N = 113 (100%)

 ≥ 10

81 (55.9%)

27 (23.9%)

 < 10

64 (44.1%)

86 (76.1%)